MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 4:318-320, (2004)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi4.6.3
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, D. H.
Right arrow Articles by Taub, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, D. H.
Right arrow Articles by Taub, D. D.

Viewpoint

Targeting Lipids to Prevent HIV Infection

Dzung H. Nguyen1 and Dennis D. Taub2

1 School of Medicine, Glycobiology Research and Training Program, University of California, San Diego, La Jolla, California 92093-0687;
2 Laboratory of Immunology, National Institute on Aging, NIH, DHHS, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224-6825

SUMMARY

Combination drug therapies exist that combat HIV replication and the production of virions. But just as the easiest way to deal with an interloper is to keep him from entering your home rather than removing him after the fact, most studies directed at reducing HIV infection are designed to keep HIV at bay, outside the host cell. Work on keeping HIV out has progressed from early work on CD4 to the chemokine receptors CCR5 and CXCR4 found on the surface of host cells. More recently, the depletion of cholesterol, the presence of which is essential for HIV entry, has been studied as a means to subvert HIV entry, and new work by Finnegan and others suggest that another useful strategy may involve increasing the amount of the sphingolipid ceramide found in lipid rafts on the surface of host cells. Increased ceramide might inhibit HIV entry by a number of means, including the displacement of cholesterol and modifying the overall organization and structure of the lipid rafts.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Chentouf, S. Ghannam, C. Bes, S. Troadec, M. Cerutti, and T. Chardes
Recombinant Anti-CD4 Antibody 13B8.2 Blocks Membrane-Proximal Events by Excluding the Zap70 Molecule and Downstream Targets SLP-76, PLC{gamma}1, and Vav-1 from the CD4-Segregated Brij 98 Detergent-Resistant Raft Domains
J. Immunol., July 1, 2007; 179(1): 409 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. M. Finnegan, S. S. Rawat, E. H. Cho, D. L. Guiffre, S. Lockett, A. H. Merrill Jr., and R. Blumenthal
Sphingomyelinase Restricts the Lateral Diffusion of CD4 and Inhibits Human Immunodeficiency Virus Fusion
J. Virol., May 15, 2007; 81(10): 5294 - 5304.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. J. Heung, C. Luberto, and M. Del Poeta
Role of Sphingolipids in Microbial Pathogenesis
Infect. Immun., January 1, 2006; 74(1): 28 - 39.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.